Free Trial

D. E. Shaw & Co. Inc. Decreases Stock Holdings in Bioventus Inc. (NYSE:BVS)

Bioventus logo with Medical background

D. E. Shaw & Co. Inc. cut its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 160,656 shares of the company's stock after selling 160,974 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.20% of Bioventus worth $1,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of BVS. Charles Schwab Investment Management Inc. lifted its holdings in Bioventus by 11.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock worth $4,571,000 after buying an additional 45,182 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Bioventus by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 19,228 shares of the company's stock valued at $202,000 after acquiring an additional 1,652 shares in the last quarter. Vanguard Group Inc. lifted its stake in Bioventus by 18.7% in the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock worth $25,852,000 after acquiring an additional 388,174 shares during the period. Barclays PLC lifted its stake in Bioventus by 31.0% in the fourth quarter. Barclays PLC now owns 66,337 shares of the company's stock worth $696,000 after acquiring an additional 15,683 shares during the period. Finally, Spire Wealth Management bought a new stake in Bioventus in the fourth quarter valued at $402,000. 62.94% of the stock is owned by institutional investors.

Bioventus Price Performance

Shares of NYSE:BVS remained flat at $6.53 during trading on Tuesday. The stock had a trading volume of 332,477 shares, compared to its average volume of 456,262. Bioventus Inc. has a 12-month low of $5.28 and a 12-month high of $14.38. The company has a market cap of $536.40 million, a P/E ratio of -10.70 and a beta of 0.95. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The company has a 50 day moving average of $7.66 and a two-hundred day moving average of $9.56.

Insider Activity

In related news, CFO Mark Leonard Singleton sold 5,479 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $9.79, for a total value of $53,639.41. Following the sale, the chief financial officer now owns 131,963 shares in the company, valued at $1,291,917.77. This represents a 3.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 13,330 shares of company stock worth $115,291. Insiders own 32.90% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on BVS shares. Canaccord Genuity Group restated a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a research report on Wednesday, May 7th.

Get Our Latest Stock Report on BVS

Bioventus Profile

(Free Report)

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

Recommended Stories

Institutional Ownership by Quarter for Bioventus (NYSE:BVS)

Should You Invest $1,000 in Bioventus Right Now?

Before you consider Bioventus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.

While Bioventus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Congress Bought This Stock at the Bottom—Will You Miss It?
The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines